Drug intelligence / Profile preview

funakizumab

Development stage: Unknown
Lead developer: The Seventh Affiliated Hospital, Sun Yat-Sen University
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous

Overview

Funakizumab is a monoclonal antibody currently under clinical investigation for the treatment of active spondyloarthritis. Developed by The Seventh Affiliated Hospital of Sun Yat-sen University, it is being evaluated in the V-SPA study, a prospective, single-arm, multicenter trial to assess its efficacy and safety in adult patients. While the specific molecular target (such as IL-17, TNF, or IL-23) is not explicitly detailed in the initial registry summary, its nomenclature and indication suggest it is a biologic immunomodulator designed to address the inflammatory pathways characteristic of spondyloarthritis.

Targets

IL-17A (Interleukin-17A)

Beyond the preview

Go deeper on funakizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on funakizumab.

Explore the full profile